BDX
Becton DickinsonPrevious close
181.85
Change
−4.07 / −2.19%
52-Week Range
140.11 – 213.08
P/E (TTM)
52.6
Forward P/E
12.4
Based on consensus earnings for the next 12 months
Market Cap
$49.5B
1M
−0.13%
S&P 500 −2.41% over same period
Volume / Avg Volume
1.7M / 1.6M
1.07× average
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | EPS Actual / Est. | Analysis |
|---|---|---|---|---|
| FY2026 Q3 Quarter ended 2026-06 | 2026-08-06 | $5.0B | 3.23 / 3.17 | Read analysis → |
| FY2026 Q2 Quarter ended 2026-03 | 2026-04-02 | $4.7B | 2.90 / 2.80 | Pending |
| FY2026 Q1 Quarter ended 2025-12 | 2026-02-09 | — | — / — | Pending |
| FY2025 Q4 Quarter ended 2025-09 | 2025-10-15 | — | — / — | Pending |
| FY2025 Q3 Quarter ended 2025-06 | 2025-08-07 | — | — / — | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 88 of its 5-year rangeExpensive
5-year range 25.9 – 56.7 · Median 39.2
Last 4 quarters: $2.5B in buybacks + $1.2B in dividends, 7.41% of market cap combined
P/E (TTM)
52.6
P/B
2.0
P/S
2.4
Dividend Yield
1.59%
Earnings Reaction
Over the last 5 reports, the stock moved ±4.4% on average on the first trading day after, rising 2 times
Most recent −0.12%
Volatility & Correlation
1-year beta 0.39 · Correlation with S&P 500 0.16Low beta
Annualized volatility 31% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 6 · $1.4MNet selling $1.4M
- 08-26Feld MichaelEVP, Chief Revenue OfficerSell$0.03M165 shares · Avg price 188.49
- 08-13Polen Thomas E JrChairman, CEO and PresidentSell$0.77M4,152 shares · Avg price 185.00
- 08-11Goette RolandEVP and President, EMEASell$0.44M2,438 shares · Avg price 180.84
- 07-27Feld MichaelEVP, Chief Revenue OfficerSell$0.01M75 shares · Avg price 157.13
- 06-26Feld MichaelEVP, Chief Revenue OfficerSell$0.01M75 shares · Avg price 152.80
- 06-24Garrison Michael DavidEVP & Pres Med.Essntl&BioPharmSell$0.16M1,100 shares · Avg price 145.66
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 4.98 | +5.4% | 46.5% | 0.38 | 1.37 |
| FY2026 Q2 | 4.71 | +5.2% | 45.7% | -0.31 | -1.11 |
| FY2026 Q1 | 5.25 | +1.6% | 45.9% | 0.38 | 1.34 |
| FY2025 Q4 | 7.47 | +37.3% | 48.1% | 0.49 | 1.71 |
| FY2025 Q3 | 4.73 | −5.3% | 47.3% | 0.57 | 2.00 |
| FY2025 Q2 | 4.48 | −11.2% | 41.5% | 0.31 | 1.07 |
| FY2025 Q1 | 5.17 | +9.8% | 43.2% | 0.30 | 1.04 |
| FY2024 Q4 | 5.44 | +6.9% | 45.7% | 0.40 | 1.37 |
| FY2024 Q3 | 4.99 | +2.3% | 46.2% | 0.49 | 1.68 |
| FY2024 Q2 | 5.05 | +4.6% | 45.7% | 0.54 | 1.85 |
| FY2024 Q1 | 4.71 | +2.6% | 43.1% | 0.28 | 0.96 |
| FY2023 Q4 | 5.09 | +6.8% | 33.5% | 0.11 | 0.35 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| BDX | 52.6 | +5.4% | 46.5% | −0.13% | Neutral |
| LLY | 39.9 | +47.7% | 85.8% | −3.83% | Bullish |
| JNJ | 30.6 | +6.6% | 68.2% | +1.87% | Bullish |
| ABBV | 73.7 | +10.2% | 74.7% | +4.87% | Neutral |
| MRK | 112.2 | +5.1% | 73.5% | +6.57% | Neutral |
| UNH | 23.9 | +0.4% | 88.1% | −5.15% | Neutral |
| TMO | 34.4 | +10.5% | — | +10.75% | Bullish |
| AMGN | 23.3 | +9.5% | 72.0% | −10.26% | Neutral |
| GILD | — | +10.2% | 79.8% | +6.31% | Neutral |